Abstract
Understanding the underlying causes of congenital anomalies (CAs) can be a complex diagnostic journey. We aimed to assess the efficiency of exome sequencing (ES) and chromosomal microarray analysis (CMA) in patients with CAs among a population with a high fraction of consanguineous marriage. Depending on the patient’s symptoms and family history, karyotype/Quantitative Fluorescence- Polymerase Chain Reaction (QF-PCR) (n = 84), CMA (n = 81), ES (n = 79) or combined CMA and ES (n = 24) were performed on 168 probands (66 prenatal and 102 postnatal) with CAs. Twelve (14.28%) probands were diagnosed by karyotype/QF-PCR and seven (8.64%) others were diagnosed by CMA. ES findings were conclusive in 39 (49.36%) families, and 61.90% of them were novel variants. Also, 64.28% of these variants were identified in genes that follow recessive inheritance in CAs. The diagnostic rate (DR) of ES was significantly higher than that of CMA in children from consanguineous families (P = 0·0001). The highest DR by CMA was obtained in the non-consanguineous postnatal subgroup and by ES in the consanguineous prenatal subgroup. In a population that is highly consanguineous, our results suggest that ES may have a higher diagnostic yield than CMA and should be considered as the first-tier test in the evaluation of patients with congenital anomalies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
References
World Health Organization. Congenital anomalies. Fact sheet N 370. Available at who int/mediacentre/factsheet/fs370/en. 2015.
Guide E. Instruction for the registration of congenital anomalies. Eurocat Cent Registry Dept Epidemiol, Cathol Univ Louvian, Bruss Pp. 1990;153:157.
Martínez‐Frías M, Bermejo E, Frias J. Pathogenetic classification of a series of 27,145 consecutive infants with congenital defects. Am J Med Genet. 2000;90:246–9.
Garne E, Dolk H, Loane M, Wellesley D, Barisic I, Calzolari E, et al. Paper 5: Surveillance of multiple congenital anomalies: implementation of a computer algorithm in European registers for classification of cases. Birth Defects Res Part A: Clin Mol Teratol. 2011;91:S44–50.
Dobrescu MA, Burada F, Cucu MG, Riza AL, Chelu G, Plesea RM, et al. Prenatal genetic counseling in congenital anomalies. congenital anomalies-from the embryo to the neonate: IntechOpen. 2018.
Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease. Circulation Res. 2017;120:923–40.
Vivante A, Kohl S, Hwang D-Y, Dworschak GC, Hildebrandt F. Single-gene causes of congenital anomalies of the kidney and urinary tract (CAKUT) in humans. Pediatr Nephrol. 2014;29:695–704.
Leslie EJ, Marazita ML, editors. Genetics of cleft lip and cleft palate. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; 2013: Wiley Online Library.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.
Carss KJ, Hillman SC, Parthiban V, McMullan DJ, Maher ER, Kilby MD, et al. Exome sequencing improves genetic diagnosis of structural fetal abnormalities revealed by ultrasound. Hum Mol Genet. 2014;23:3269–77.
He M, Du L, Xie H, Zhang L, Gu Y, Lei T, et al. The added value of whole-exome sequencing for anomalous fetuses with detailed prenatal ultrasound and postnatal phenotype. Front Genet. 2021;12:627204.
Vora NL, Powell B, Brandt A, Strande N, Hardisty E, Gilmore K, et al. Prenatal exome sequencing in anomalous fetuses: new opportunities and challenges. Genet Med. 2017;19:1207.
Hsu R-H, Lee C-H, Chien Y-H, Hwu P, Lee N-C. eP146: application of exome sequencing in patients of congenital anomalies with or without intellectual disability. Genet Med. 2022;24:S90.
Weh E, Reis LM, Happ HC, Levin AV, Wheeler PG, David KL, et al. Whole exome sequence analysis of Peters anomaly. Hum Genet. 2014;133:1497–511.
Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21.
Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:2029–37.
Rashidi-Nezhad A, Fakhri L, Hantoush Zadeh S, Amini E, Sajjadian N, Hossein Zadeh P, et al. Evaluating the pre-, peri-and post-natal conditions of neonates affected by multiple congenital anomalies: a brief report. Tehran Univ Med J. 2013;70:659–64.
Network NBDP. Appendix 3.1. Birth defects descriptions for NBDPN core, recommended, and extended conditions. Guidelines for conducting birth defects surveillance Atlanta, GA: National Birth Defects Prevention Network. 2015.
Rashidi-Nezhad A, Parvaneh N, Farzanfar F, Azimi C, Harewood L, Akrami SM, et al. 2q34-qter duplication and 4q34. 2-qter deletion in a patient with developmental delay. Eur J Med Genet. 2012;55:203–10.
Badv RS, Mahdiannasser M, Rasoulinezhad M, Habibi L, Rashidi-Nezhad A. CEP104 gene may involve in the pathogenesis of a new developmental disorder other than joubert syndrome. Mol Biol Rep. 2022;49:7231–7.
Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Elsevier; 2020.
McGowan-Jordan J, Hastings RJ, Moore S ISCN 2020: an international system for human cytogenomic nomenclature (2020). (No Title). 2020.
Mahdiannasser M, Rashidi-Nezhad A, Badv RS, Akrami SM. Exploring the genetic etiology of drug-resistant epilepsy: incorporation of exome sequencing into practice. Acta Neurol Belgica. 2022;122:1457–68.
Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–23.
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6.
Moorthie S, Blencowe H, Darlison MW, Lawn J, Morris JK, Modell B, et al. Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. J community Genet. 2018;9:387–96.
Ely DM, Driscoll AK Infant mortality in the United States, 2017: data from the period linked birth/infant death file. 2019.
Staebler M, Donner C, Van Regemorter N, Duprez L, De Maertelaer V, Devreker F, et al. Should determination of the karyotype be systematic for all malformations detected by obstetrical ultrasound? Prenat Diagn. 2005;25:567–73.
Vand-Rajabpour F, Mousavi F, Kariminejad R, Bagherizadeh I, Bahadory K, Giti S, et al. Evaluation and Report of Array-CGH Utility in prenatal and postnatal diagnosis and abortion products referred to a Diagnostic Laboratory in Tehran. Sarem J Med Res. 2021;6:135–41.
Evangelidou P, Sismani C, Ioannides M, Christodoulou C, Koumbaris G, Kallikas I, et al. Clinical application of whole-genome array CGH during prenatal diagnosis: Study of 25 selected pregnancies with abnormal ultrasound findings or apparently balanced structural aberrations. Mol Cytogenetics. 2010;3:1–10.
Castells-Sarret N, Cueto-González AM, Borregan M, López-Grondona F, Miró R, Tizzano E, et al. Comparative genomic hybridisation as a first option in genetic diagnosis: 1000 cases and a cost–benefit analysis. An de Pediatría (Engl Ed). 2018;89:3–11.
Sagoo GS, Butterworth AS, Sanderson S, Shaw-Smith C, Higgins JP, Burton H. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med. 2009;11:139–46.
Najafi K, Gholami S, Moshtagh A, Bazrgar M, Sadatian N, Abbasi G, et al. Chromosomal aberrations in pregnancy and fetal loss: Insight on the effect of consanguinity, review of 1625 cases. Mol Genet Genom Med. 2019;7:e820.
Mohammadzadeh A, Akbaroghli S, Aghaei-Moghadam E, Mahdieh N, Badv RS, Jamali P, et al. Investigation of chromosomal abnormalities and microdeletion/microduplication (s) in fifty Iranian patients with multiple congenital anomalies. Cell J (Yakhteh). 2019;21:337.
Drury S, Williams H, Trump N, Boustred C, GOSGene, Lench N, et al. Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities. Prenat Diagn. 2015;35:1010–7.
Ales M, Luca L, Marija V, Gorazd R, Karin W, Ana B, et al. Phenotype-driven gene target definition in clinical genome-wide sequencing data interpretation. Genet Med. 2016;18:1102.
Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18:696–704.
Nambot S, Thevenon J, Kuentz P, Duffourd Y, Tisserant E, Bruel A-L, et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis. Genet Med. 2018;20:645–54.
Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–9.
Najafi K, Mehrjoo Z, Ardalani F, Ghaderi-Sohi S, Kariminejad A, Kariminejad R, et al. Identifying the causes of recurrent pregnancy loss in consanguineous couples using whole exome sequencing on the products of miscarriage with no chromosomal abnormalities. Sci Rep. 2021;11:1–12.
Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867–74.
Vissers LE, Van Nimwegen KJ, Schieving JH, Kamsteeg E-J, Kleefstra T, Yntema HG, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19:1055–63.
Jegathisawaran J, Tsiplova K, Ungar WJ A microcosting and cost-consequence analysis of genomic testing strategies (including trios) in autism spectrum disorder: an update. The Hospital for Sick Children: Technology Assessment at SickKids. 2019.
Acknowledgements
We are thankful to the all participants and their parents who have shown enthusiasm towards this project. We are grateful to the all nurses and other medical staffs who helped us in this project.
Funding
This study was supported by Tehran University of Medical Sciences through two grants to A.R.N. (grant no. 52367) and S.M.A. (grant no. 52355).
Author information
Authors and Affiliations
Contributions
Conceptualization: H.V., J.A.N., Y.C., S.M.A.; Supervision: S.M.A., A.R.N; Writing-original draft: H.V., S.M.A., A.R.N.; Data curation: H.V., L.H., Y.C., A.M., R.G., A.R.N.; Validation: H.V., N.F., R.R.N., T.S., M.M., M.M.D., R.K., A.R.N.; Software: A.A.; Resources: H.D., F.R.S., M.R.Z., V.G., P.S., A.N., T.E.S., Z.M., B.S., F.G., M.S., S.S., R.M., A.H., M.A.D.; Writing-review & editing: J.A.N., Y.C., R.G., A.H., S.M.A., A.R.N. All the authors approved the final draft.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. In particular, this research was conducted with the voluntary, informed consent of any research participants, free of coercion or coercive circumstances, and approval was granted by the research ethics committee of Tehran University of Medical Sciences (No. IR.TUMS.MEDICINE.REC.1399.1278).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Vaseghi, P., Habibi, L., Neidich, J.A. et al. Towards solving the genetic diagnosis odyssey in Iranian patients with congenital anomalies. Eur J Hum Genet (2024). https://doi.org/10.1038/s41431-024-01533-x
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41431-024-01533-x
This article is cited by
-
Optimizing genetic testing strategies for congenital anomalies in Iran
European Journal of Human Genetics (2024)